Drug Profile
BMS 938790
Alternative Names: BMS938790Latest Information Update: 28 Mar 2018
Price :
$50
*
At a glance
- Originator Adnexus Therapeutics
- Developer Bristol-Myers Squibb
- Class Anti-inflammatories; Fibronectins; Polyethylene glycols; Proteins
- Mechanism of Action Interleukin 23 stimulants; STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Mar 2018 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in USA (IV)
- 28 Mar 2018 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in USA (SC)
- 15 Mar 2015 Pharmacokinetic, pharmacodynamic and adverse event data from a phase I trial in healthy volunteers released by Bristol-Myers Squibb